Meeting
2023 ASCO Annual Meeting
UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.
Authors
Debra L. Richardson
Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, Oklahoma City, OK
Debra L. Richardson , Philipp Harter , David M. O'Malley , Antonio Gonzalez Martin , Thomas J. Herzog , Caroline Rogalski , Rita Lemming , Erika Keeton , Robert Allen Burger , Mansoor Raza Mirza
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT05329545
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS5614)
DOI
10.1200/JCO.2023.41.16_suppl.TPS5614
Abstract #
TPS5614
Poster Bd #
308a
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Triplet maintenance (olaparib, pembrolizumab, and bevacizumab) in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer: A multi-center, single-arm phase II study (OPEB-01).
First Author: Yoo Na Kim
Poster
2022 ASCO Annual Meeting
Integrated safety summary of single-agent mirvetuximab soravtansine in patients with folate receptor α (FRα)-positive recurrent ovarian cancer: Phase 1 and 3 clinical trials.
First Author: Kathleen N. Moore
Poster
2019 ASCO Annual Meeting
Phase 2 trial of tisotumab vedotin in platinum-resistant ovarian cancer (innovaTV 208).
First Author: Haider Mahdi
First Author: David M. O'Malley